Clinical risk factors for poor anatomic response to ranibizumab in neovascular age-related macular degeneration

Open Ophthalmology Journal

Volumn 8, Issue , 2014, Pages 3-6

  Guber, Josef ^a   Josifova, Tatjana ^b   Henrich, Paul Bernhard ^b   Guber, Ivo ^c  

^a EPSOM AND ST HELIER UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF BASEL   (Switzerland)

^c CANTONAL HOSPITAL WINTERTHUR   (Switzerland)

Author keywords

Age related macular degeneration; Lucentis; Poor responder; Ranibizumab; Risk factors

Indexed keywords

RANIBIZUMAB;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CENTRAL RETINAL THICKNESS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA CYSTOID EDEMA; RISK FACTOR; SEX DIFFERENCE; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; VERY ELDERLY; VISUAL ACUITY;

EID: 84924127010     PISSN: None     EISSN: 18743641     Source Type: Journal    
DOI: 10.2174/1874364101408010003     Document Type: Article

References (16)

1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA 2004; 291:1900-1
2. Friedmann DS, O'Colmain BJ, Munoz B, et al. Prevalence of agerelated macular degeneration in the United States. Arch Ophthalmol 2004; 122: 564-72
3. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102: 1640-42
4. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006; 26: 859-70
5. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31
6. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-44
7. Regillo CD, Brown DM, Abraham P, et al. Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular agerelated macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145: 239-48
8. Schmidt-Erfurth U, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE Study. Ophthalmology 2011; 118: 831-9
9. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009; 148(1): 43-58.e1. doi: 10.1016/j.ajo.2009.01.024
10. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143: 566-83
11. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010, 94(1): 2-13
12. Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN Study. Ophthalmology 2011; 118: 663-71
13. Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 2008; 15(12): 2199-205
14. Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT. Tachyphylaxis after intravitreal bevacizumab for exudative agerelated macular degeneration. Retina 2009; 29(6): 723-31
15. Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup analysis of the MARINA Study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007; 114: 246-52
16. McKibbin M, Ali M, Bansal S, et al. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Br J Ophthalmol 2012; 96(2): 208-12.